Not yet recruiting NCT04345406
Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ACEIs, Conventional treatment.
- Who it may be relevant to
- Registry conditions: COVID. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Randomized Trial of ACEIs in Treatment of COVID-19
Overview
ACEIs as treatment for COVID19
Detailed description
ACEIs as suggested treatment for COVID19
Interventions
- Drug ACEIs
Captopril or enalapril - Drug Conventional treatment
alexoquine
Primary outcome measures
- number of patients with virological cure [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Patients infected with covid 19
Exclusion criteria
- allergy or contraindications to the drug
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT04345406 · ACEIS COVID 19